Skip to main content
S&P 5007,561.67-0.40%DOW52,347.55+0.10%NASDAQ25,136.27-0.91%BTC$68,258.00-3.68%ETH$1,927.42-4.09%GOLD$3,887.60+0.06%OIL$88.92+0.20%
Smart Investors Daily
SID Premium
CN

NASDAQ · CNMD

CONMED Corporation

Healthcare · Medical - Devices

$50.59

Up+$0.11 (+0.22%)

Updated Nov 15, 2026, 12:38 AM

SID Score

6.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.23B
P/E ratio
11.17
Dividend yield
1.58%
52-week range
$31.44 – $54.80
Volume
189.72K
Avg. volume
469.39K

Price performance · CNMD

CNMD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

CNMD closed at $50.59 after 20 trading sessions, up 9.86% for the selected period.

Last close
$50.59
Period change
+9.86%
Period low
$44.29
Period high
$53.66
Daily close
View OHLC price history
CNMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$51.45$51.45$50.40$50.59189.72K
Nov 12, 2026$51.43$51.43$50.17$50.48217.93K
Nov 11, 2026$50.51$51.5599$50.50$50.77204.86K
Nov 10, 2026$51.31$51.64$50.25$51.21225.16K
Nov 9, 2026$52.05$52.755$51.19$51.94375.68K
Nov 6, 2026$51.11$52.39$51.11$51.50331.56K
Nov 5, 2026$54.40$54.80$51.705$52.83406.92K
Nov 4, 2026$47.99$53.73$47.99$53.66592.35K
Nov 3, 2026$46.71$47.7856$46.25$47.23510.1K
Nov 2, 2026$44.76$47.24$44.76$46.59444.23K
Oct 30, 2026$45.71$46.33$43.67$44.29404.08K
Oct 29, 2026$43.60$46.47$43.50$45.72482.19K
Oct 28, 2026$47.40$48.09$45.12$45.76610.18K
Oct 27, 2026$48.09$48.09$46.53$47.20505.95K
Oct 26, 2026$48.78$49.73$47.56$47.68386.61K
Oct 23, 2026$49.03$49.72$48.31$49.25343.26K
Oct 22, 2026$47.38$49.56$47.38$49.44398.58K
Oct 21, 2026$46.92$47.80$46.54$47.11442.96K
Oct 20, 2026$45.815$48.00$45.815$47.58440.15K
Oct 19, 2026$46.49$47.06$45.89$46.05342.34K

Latest CNMD news

The latest Smart Investors Daily articles mentioning CNMD.

Stock researchCompany · Overview

CNMD research

Overview

Company profile and research snapshot.

Company profile

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$78.00
Implied upside
—
Analysts
—
CNMD recent ratings
DateFirmRatingTarget
Oct 29, 2026JP MorganNeutral—
Oct 29, 2026Wells FargoEqual-Weight—
Jul 30, 2026Piper SandlerNeutral—
Jul 30, 2026Wells FargoEqual-Weight—
Jul 9, 2026BMO CapitalMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 7, 2026

CONMED (CNMD) Stock Looks Like A Bargain Despite Its 65% Fall

CONMED shares closed at US$51.50, and the recent rebound raises a straightforward question for you as an investor: Is that price supported by what the business is earning today, given how rough the longer term has been for the stock? The share price has fallen 64.7% over 5 years, which puts the focus squarely on whether current earnings now justify where the valuation has reset to. The group depends heavily on consistent procedure volumes and disciplined cost control, so any change in...

Yahoo · Nov 3, 2026

CNMD Q3 deep dive: stable revenue, margin improvement, and focus on core growth platforms

Medical tech company CONMED (NYSE:CNMD) met Wall Street’s revenue expectations in Q3 2026, but sales were flat year on year at $335.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.36 billion at the midpoint. Its non-GAAP profit of $1.04 per share was 3.7% above analysts’ consensus estimates.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By